DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.
作者信息
Casellas Román Heidi L, Venugopal Kartika, Feng Yang, Shabashvili Daniil E, Posada Luisa M, Li Jianping, Guryanova Olga A
机构信息
Department of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL, United States; Department of Pharmacology and Toxicology, University of Puerto Rico School of Medicine, Medical Sciences Campus, San Juan, PR, Puerto Rico.
Department of Pharmacology & Therapeutics, University of Florida College of Medicine, Gainesville, FL, United States.
出版信息
Leuk Res. 2020 Jul;94:106372. doi: 10.1016/j.leukres.2020.106372. Epub 2020 May 13.
Abstract
摘要
相似文献
1
DNMT3A alterations associated with myeloid malignancies dictate differential responses to hypomethylating agents.与髓系恶性肿瘤相关的DNMT3A改变决定了对低甲基化药物的不同反应。
Leuk Res. 2020 Jul;94:106372. doi: 10.1016/j.leukres.2020.106372. Epub 2020 May 13.
2
Clinical development of demethylating agents in hematology.血液学中去甲基化剂的临床开发。
J Clin Invest. 2014 Jan;124(1):40-6. doi: 10.1172/JCI69739. Epub 2014 Jan 2.
3
Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.中国急性髓系白血病和骨髓增生异常综合征患者中反复出现的 DNMT3A R882 突变。
PLoS One. 2011;6(10):e26906. doi: 10.1371/journal.pone.0026906. Epub 2011 Oct 31.
4
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy.男性中 CDA 表达/活性的增加导致胞苷类似物半衰期缩短，可能导致 5-氮杂胞苷或地西他滨治疗效果更差。
Clin Cancer Res. 2013 Feb 15;19(4):938-48. doi: 10.1158/1078-0432.CCR-12-1722. Epub 2013 Jan 3.
5
Opposing effects of acute versus chronic inhibition of p53 on decitabine's efficacy in myeloid neoplasms.急性抑制与慢性抑制 p53 对地西他滨治疗骨髓增生异常肿瘤疗效的相反作用。
Sci Rep. 2019 Jun 3;9(1):8171. doi: 10.1038/s41598-019-44496-6.
6
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.异柠檬酸脱氢酶1（IDH1）、异柠檬酸脱氢酶2（IDH2）及DNA甲基转移酶3A（DNMT3A）突变与接受去甲基化药物治疗的老年急性髓系白血病患者预后之间不存在相关性。
Leuk Lymphoma. 2014 Aug;55(8):1925-9. doi: 10.3109/10428194.2013.855309. Epub 2014 Feb 4.
7
Recurrent DNMT3A mutations in patients with myelodysplastic syndromes.骨髓增生异常综合征患者中反复出现的 DNMT3A 突变。
Leukemia. 2011 Jul;25(7):1153-8. doi: 10.1038/leu.2011.44. Epub 2011 Mar 18.
8
Oligomerization of DNMT3A controls the mechanism of de novo DNA methylation.DNMT3A 寡聚化控制从头 DNA 甲基化的机制。
J Biol Chem. 2011 Dec 2;286(48):41479-41488. doi: 10.1074/jbc.M111.284687. Epub 2011 Oct 6.
9
DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.DNMT3A突变介导急性髓系白血病中致白血病因子MEIS1的表观遗传重新激活。
Oncogene. 2016 Jun 9;35(23):3079-82. doi: 10.1038/onc.2015.359. Epub 2015 Oct 5.
10
Rare occurrence of DNMT3A mutations in myelodysplastic syndromes.DNMT3A 突变在骨髓增生异常综合征中罕见发生。
Haematologica. 2011 Dec;96(12):1870-3. doi: 10.3324/haematol.2011.045559. Epub 2011 Aug 31.
引用本文的文献
1
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations.联合策略增强携带和不携带 DNMT3A 突变的急性髓系白血病对阿糖胞苷诱导的复制应激的敏感性。
Exp Hematol. 2022 Jun;110:20-27. doi: 10.1016/j.exphem.2022.03.008. Epub 2022 Mar 16.
2
Alterations to in Hematologic Malignancies.血液系统恶性肿瘤中的 改变。
Cancer Res. 2021 Jan 15;81(2):254-263. doi: 10.1158/0008-5472.CAN-20-3033. Epub 2020 Oct 21.
本文引用的文献
1
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes.TP53 等位基因状态对骨髓增生异常综合征的基因组稳定性、临床表现和预后的影响。
Nat Med. 2020 Oct;26(10):1549-1556. doi: 10.1038/s41591-020-1008-z. Epub 2020 Aug 3.
2
Distinct clinical and biological implications of various DNMT3A mutations in myeloid neoplasms.髓系肿瘤中各种DNMT3A突变的不同临床和生物学意义。
Leukemia. 2018 Feb;32(2):550-553. doi: 10.1038/leu.2017.295. Epub 2017 Sep 22.
3
Tracing the origins of relapse in acute myeloid leukaemia to stem cells.追溯急性髓系白血病复发的根源到干细胞。
Nature. 2017 Jul 6;547(7661):104-108. doi: 10.1038/nature22993. Epub 2017 Jun 28.
4
Hypomethylating Agents as a Therapy for AML.低甲基化剂作为急性髓系白血病的一种治疗方法。
Curr Hematol Malig Rep. 2017 Feb;12(1):1-10. doi: 10.1007/s11899-017-0363-4.
5
DNMT3A in Leukemia.白血病中的DNA甲基转移酶3A（DNMT3A）
Cold Spring Harb Perspect Med. 2017 Feb 1;7(2):a030320. doi: 10.1101/cshperspect.a030320.
6
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling.DNMT3A突变通过受损的核小体重塑促进急性髓性白血病对蒽环类药物的耐药性。
Nat Med. 2016 Dec;22(12):1488-1495. doi: 10.1038/nm.4210. Epub 2016 Nov 14.
7
Targeting the cancer epigenome for therapy.针对癌症表观基因组进行治疗。
Nat Rev Genet. 2016 Sep 15;17(10):630-41. doi: 10.1038/nrg.2016.93.
8
Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia.急性髓系白血病中对去甲基化药物治疗反应的突变相关性
Haematologica. 2016 Nov;101(11):e457-e460. doi: 10.3324/haematol.2016.148999. Epub 2016 Jul 14.
9
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells.Dnmt3a调控造血干细胞和祖细胞的骨髓增殖及肝脏特异性扩增。
Leukemia. 2016 May;30(5):1133-42. doi: 10.1038/leu.2015.358. Epub 2015 Dec 29.
10
The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers.R882H DNMT3A 突变与 AML 相关，通过阻断其形成活性四聚体的能力，显性抑制野生型 DNMT3A。
Cancer Cell. 2014 Apr 14;25(4):442-54. doi: 10.1016/j.ccr.2014.02.010. Epub 2014 Mar 20.
Zotero 插件